AdRoll Group Rebrands as NextRoll, Launches Marketing Platform Services
AdRoll Group today announced it has rebranded as NextRoll, Inc., a marketing and data technology company. Additionally, NextRoll is introducing external APIs to open its infrastructure, technology and data to a wide array of new companies. NextRoll is now comprised of three business units: RollWorks, an account-based platform for B2B marketing and sales teams; AdRoll, a growth marketing platform for direct-to-consumer (DTC) brands; and NextRoll Platform Services, a marketing-technology-as-a-service offering for brands, agencies, marketplaces, publishers, and marketing platforms to enhance current marketing capabilities or enable new revenue streams.
As online marketing has become more complex, many companies must choose between building their own technology stacks or working with closed-system providers, which can result in losing control, flexibility and customer insight. Now, with NextRoll Platform Services, companies can access leading marketing technology, data and channels without sacrificing relationships with their key audiences. For example, marketplaces can improve demand generation by giving their customers access to premium tools and audiences from NextRoll.
NextRoll Platform Services leverages rich data assets for unified, people-based profiles across first-, second- and third-party data, including more than 500 million identities and 1 billion devices. Additionally, NextRoll’s machine-learning capabilities enable companies to provide marketing messages, activate curated audiences and measure which efforts drive the greatest impact. NextRoll Platform Services customers can scale as needed, with a global infrastructure that covers 110 countries and manages up to five petabytes of stored data and 12 trillion real-time events processed daily.
“We’ve built an unrivaled marketing and data technology stack that enables marketers to better understand and engage with their audiences to make measurable decisions,” said Toby Gabriner, CEO of NextRoll. “With our new NextRoll Platform Services, we can offer these benefits to more companies, and allow them to innovate on top of our offerings. As we launch NextRoll Platform Services, it’s clear we’ve grown beyond our old name. Today, NextRoll is a marketing and data technology company.”
Services available today include:
Channels-as-a-Service
Channels-as-a-Service from NextRoll Platform Services allows businesses to expand their marketing solutions to new channels, including display ads, social media, native ads, email and video across devices enabling their customers to attract and re-engage audiences. With integrations to over 20 publishers and exchanges from Channels-as-a-Service, users can access the best inventory at any time to accelerate budget fulfillment and hit performance goals. They also gain granular insights into conversion, audience, performance and delivery data.
Audiences-as-a-Service
Many companies end up with vast amounts of raw audience data that is difficult to comprehend. With Audiences-as-a-Service from NextRoll Platform Services, companies have a unified and normalized view across identities and platforms within their existing data set, turning data into targetable segments they can ingest at scale and use in real-time. With this view, companies can better understand and serve each customer or segment. Companies can also enrich internal user profiles by leveraging the NextRoll database or package up these audience insights into premium, targetable segments for resale.
NextRoll Platform Services currently has 10 large customers that drive nearly $1 million in revenue per month, and has significant traction in the pipeline. A key contributor to the momentum is an existing joint venture with Rakuten in the Japanese market that leverages NextRoll Platform Services.
NextRoll Platform Services will release additional offerings in 2020 and beyond. Developers can access integration toolkits here.
About NextRoll
NextRoll, Inc. is a marketing and data technology company on a mission to accelerate growth for companies, big and small. Since 2007, our technology has powered a suite of data-driven marketing solutions and services. NextRoll Platform Services offer marketing-technology-as-a-service for brands, agencies, marketplaces, publishers and marketing platforms, to create more value for their business. Ambitious DTC brands use AdRoll products to make their display, social, and email advertising work together to accelerate business growth. RollWorks offers ambitious B2B companies an account-based platform to align their marketing and sales teams and confidently grow revenue. NextRoll empowers over 37,000 customers worldwide to understand, attract and engage buyers, driving growth for their businesses.
NextRoll is a privately-held company headquartered in San Francisco, CA. Company products honor the best practices for data use and privacy of leading associations including the Network Advertising Initiative (NAI) and the Digital Advertising Alliance’s (DAA) App Choices programs. Learn more about NextRoll at nextroll.com
AdRoll, NextRoll and RollWorks are trademarks NextRoll.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005355/en/
Contact information
Jeanette Jordan
Director of Marketing
nextrollus@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom